Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial

Stallard, 1999, Decision theoretic designs for phase II clinical trials with multiple outcomes, Biometrics, 55, 971, 10.1111/j.0006-341X.1999.00971.x

Berry, 1989, Monitoring accumulating data in a clinical trial, Biometrics, 45, 1197, 10.2307/2531771

Berry, 2006, Bayesian clinical trials, Nat Rev Drug Discov, 5, 27, 10.1038/nrd1927

Brunier, 1994, Sample sizes for phase II clinical trials derived from Bayesian decision theory, Stat Med, 13, 2493, 10.1002/sim.4780132312

Stallard, 2003, Decision-theoretic designs for phase II clinical trials allowing for competing studies, Biometrics, 59, 402, 10.1111/1541-0420.00047

Stallard, 2001, Stopping rules for phase II studies, Br J Clin Pharmacol, 51, 523, 10.1046/j.0306-5251.2001.01381.x

Thall, 1994, A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials, Control Clin Trials, 15, 463, 10.1016/0197-2456(94)90004-3

Thall, 1996, New statistical strategy for monitoring safety and efficacy in single-arm clinical trials, J Clin Oncol, 14, 296, 10.1200/JCO.1996.14.1.296

Gupta, 2004

Tan, 2002, Bayesian re-assessment of two phase II trials of gemcitabine in metastatic nasopharyngeal cancer, Br J Cancer, 86, 843, 10.1038/sj.bjc.6600199

Thall, 1993, A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation, Stat Med, 12, 1197, 10.1002/sim.4780121303

Spiegelhalter, 2004

Gelman, 1995

Berry, 1993, A case for Bayesianism in clinical trials, Stat Med, 12, 1377, 10.1002/sim.4780121504

Mayo, 2004, Bayesian sample size calculations in phase II clinical trials using informative conjugate priors, Control Clin Trials, 25, 157, 10.1016/j.cct.2003.11.006

FDA FaDA: Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials — Draft Guidance for Industry and FDA Staff Rockville, MD. http://www.fda.gov/cdrh/osb/guidance/1601.html, 2006.

Farge, 2002, Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I–II study, Br J Haematol, 119, 726, 10.1046/j.1365-2141.2002.03895.x

Zohar, 2001, The continual reassessment method: Comparison of Bayesian stopping rules for dose-ranging studies, Stat Med, 20, 2827, 10.1002/sim.920

Chen, 2006, A Bayesian stopping rule for a single arm study: With a case study of stem cell transplantation, Stat Med, 25, 2956, 10.1002/sim.2429

Rousselot, 2004, A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients, Leukemia, 18, 1518, 10.1038/sj.leu.2403424

Berger, 1985

Berry, 1996